Wilson Therapeutics Progressing Its Copper Modulating Agent To Phase III

Bolstered by positive top-line Phase II trial data, Sweden-based Wilson Therapeutics will independently progress its copper modulating agent and lead asset into Phase III trials next year for the rare genetic condition known as Wilson's Disease.